Effects of cholecystokinin (CCK)-4, nonsulfated CCK-8, and sulfated CCK-8 on pancreatic somatostatin, insulin, and glucagon secretion in the dog: studies in vitro.
The effect of cholecystokinin (CCK)-4, nonsulfated CCK-8 (CCK-8), and sulfated CCK-8 (CCK-8-S) on endocrine pancreas function was investigated in the isolated perfused dog pancreas in the presence of 5.5 mM glucose. CCK-4 and CCK-8 at concentrations of 1, 10, and 100 nM dose dependently stimulated pancreatic SRIF, insulin, and glucagon release. The insulinotropic and glucagonotropic potency of CCK-8 was significantly greater than that of CCK-4, whereas the effect on SRIF secretion was similar. Furthermore, CCK-8-S and CCK-8 at concentrations of 0.1, 1, and 10 nM caused a dose-dependent increase in pancreatic A, B, and D cell secretion. The CCK-8-S was a more potent insulinotropic agent than CCK-8. It is suggested that these principal molecular CCK forms qualify for a physiological modulatory role in the endocrine pancreas.
D000818:Animals; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005755:Gastrins / Q000494:pharmacology*; D005934:Glucagon / Q000378:metabolism; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism*; D012844:Sincalide / Q000494:pharmacology*; D013004:Somatostatin / Q000378:metabolism; D013758:Tetragastrin / Q000494:pharmacology*
D005755:Gastrins; D007328:Insulin; D013758:Tetragastrin; D013004:Somatostatin; D005934:Glucagon; D012844:Sincalide